Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Apr. 08, 2022 |
Dec. 12, 2019 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
| Revenue | $ 1,096 | |||
| BioNTech Agreement [Member] | ||||
| Fees received | $ 2,750 | |||
| Deferred revenue | $ 2,750 | |||
| Revenue recognized | 688 | |||
| Revenue | $ 375 | |||
| Genentech Feasibility Study Agreement [Member] | ||||
| Revenue | $ 33 | |||
| Genentech Feasibility Study Agreement [Member] | Three Molecules [Member] | ||||
| Revenue recognized | $ 100 | |||
| Genentech Feasibility Study Agreement [Member] | Genentech [Member] | ||||
| Agreement description | Genentech paid the Company a total of $100 for the development of three molecules, or $33 per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement. | |||
| X | ||||||||||
- Definition Agreement description. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Cash received for fees during the current period. This element excludes cash proceeds from license fees. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|